ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ATE Antibe Therapeutics Inc

0.295
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Antibe Therapeutics Inc TSX:ATE Toronto Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.295 0.01 0.01 0 18:44:43

TMX Group, Antibe Therapeutics, C-Suite at The Open

26/11/2020 5:30pm

PR Newswire (Canada)


Antibe Therapeutics (TSX:ATE)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Antibe Therapeutics Charts.

TORONTO, Nov. 26, 2020 /CNW/ - Dan Legault, CEO, Antibe Therapeutics Inc. (TSX: ATE), shares his company's story in an interview with TMX Group.

 

The C-Suite at The Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange.  Videos provide insight into how company executives think in the current business environment.  To see the latest C-Suite at The Open videos visit https://www.tmxmoney.com/en/csuite.html.

About Antibe Therapeutics Inc.  (TSX: ATE)

Antibe Therapeutics Inc. develops safer, non-addictive medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The company's drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Its operating segment includes Antibe and Citagenix. The company generates maximum revenue from Citagenix segment and geographically from Canada. Citagenix segment is a marketer and distributor of regenerative medicines serving the dental and orthopaedic market places. For more information visit: http://www.antibethera.com/ 

About TMX Group (TSX: X)

TMX Group's key subsidiaries operate cash and derivative markets and clearinghouses for multiple asset classes including equities and fixed income. Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, Trayport and other TMX Group companies provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London, Beijing and Singapore. For more information about TMX Group, visit our website at www.tmx.com. Follow TMX Group on Twitter: @TMXGroup.

SOURCE TMX Group Limited

Copyright 2020 Canada NewsWire

1 Year Antibe Therapeutics Chart

1 Year Antibe Therapeutics Chart

1 Month Antibe Therapeutics Chart

1 Month Antibe Therapeutics Chart

Your Recent History

Delayed Upgrade Clock